Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Celanese","sponsor":"Alessa Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celanese Announces Collaboration with Alessa Therapeutics for the Advancement of Oncology Treatments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Celanese","sponsor":"Glaukos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celanese Announces Agreement with Glaukos Corporation for Sustained Release Glaucoma Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Celanese","sponsor":"Secarna Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Celanese","sponsor":"Glaukos","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celanese Announces Commercial Launch of Glaukos' iDose\u00ae TR (Travoprost Intracameral Implant) Using Celanese's VitalDose\u00ae Ethylene Vinyl Acetate (EVA)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Celanese

    Menu

    Celanese

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    EXCIPIENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Celanese

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies

              Details:

              The collaboration aims for the development of long-acting implants that deliver antisense oligonucleotides using Celanese VitalDose® drug delivery platform and Secarna’s proprietary ASO drug discovery and development platform.

              Lead Product(s): Undisclosed

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Secarna Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 20, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Celanese

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Celanese Announces Commercial Launch of Glaukos' iDose® TR (Travoprost Intracameral Implant) Using Celanese's VitalDose® Ethylene Vinyl Acetate (EVA)

              Details:

              iDose® TR (Travoprost Intracameral Implant) is a prostaglandin analog. It s indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension

              Lead Product(s): Travoprost

              Therapeutic Area: Ophthalmology Product Name: iDose TR

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Glaukos

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 29, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Celanese

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Celanese Announces Agreement with Glaukos Corporation for Sustained Release Glaucoma Treatment

              Details:

              Glaukos will supply its VitalDose® Drug Delivery Platform for use as a component in Glaukos’ iDose® TR (travoprost), a micro-invasive intraocular implant designed to lower intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.

              Lead Product(s): Travoprost

              Therapeutic Area: Ophthalmology Product Name: iDose TR

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Glaukos

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement April 05, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Celanese

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Celanese Announces Collaboration with Alessa Therapeutics for the Advancement of Oncology Treatments

              Details:

              VitalDose® EVA drug delivery platform will be used in the development of Alessa Therapeutics’ proprietary localized drug delivery technology. The collaboration will focus on developing a localized and sustained-release drug delivery system for oncology patients.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Recipient: Alessa Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY